Type Description Sample Clauses

Type Description. Visit 1 Within 28 days of Visit 2 Screening Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit Visit 2 Check in Day -1; Check out Day 21 Dosing on Day 1 Dosing on Day 8 Dosing on Day 15 In house stay (21 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 3 Day 30 Follow-up Outpatient visit Visit 4 Day 45 Follow-up (End of Study) Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit Part 3 (Cohort 11):
AutoNDA by SimpleDocs
Type Description. IR1. The uncertainty associated with radiometric responsivity of an OCR shall be estimated and delivered to FRMOCnet, including: the quantification of uncertainties from the radiometric calibration laboratory and their propagation; an estimation of any temporal changes in responsivity between such calibrations; and, for in-water measurements, (residual) uncertainties associated with immersion factors and possible pressure effects. The FRM4SOC-2 project deliverable D-10, using ideas from chapters 3.2, 3.4, 3.10 and 3.13 of [20], provides guidance on how to do this for the TRIOS/RAMSES and Seabird/HyperOCR OCR, while the FRM4SOC-2 project deliverable D-12 provides guidance on how to perform the laboratory measurements themselves.
Type Description. Visit 1 Within 28 days of Visit 2 Screening Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit Visit 2 Check in Day -1; Check out Day 7 Dosing on Day 1 In house stay (7 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 4 Day 14 Follow-up Outpatient visit Visit 5 Check in Day 21; Check out Day 28 Dosing on Day 22 In house stay (7 days); must fast (no food or drink other than water) for at least 8 hours before check-in Visit 6 Day 35 Follow-up Outpatient visit Visit 7 Day 52 Follow-up (End of Study) Outpatient visit; must fast (no food or drink other than water) for at least 8 hours before visit WHEN ARE YOU ELIGIBLE TO PARTICIPATE IN ANOTHER DRUG STUDY? The decision for when you can participate in another study is determined by the drug safety information gathered from the previous study. Usually, you can participate in another study as soon as 30 days after you received the last dose of drug in the study you were in. This information is true for most drugs. Some drugs may stay in your body longer and that may mean you may have to wait longer before starting another study. These results are usually only known after the last blood sample taken from you is tested to look for left-over drug. We will always make this information available to you as soon as we know. Our goal is to keep you from doing anything that may be potentially harmful to you. Your safety while participating in these studies is our primary concern. TO BE ENROLLED IN THIS STUDY You cannot be enrolled in the study if, at screening you: • Report a history of allergic reactions or oversensitivity to drugs like rezafungin or the inactive ingredients (mannitol, polysorbate 80, histidine) of the injectable form of rezafungin (Rezafungin for Injection); • experience symptoms of an illness within 14 days before the first dose of study drug, or if the Study Doctor feels you are not in good health; • if you weigh less than 50 kg (110 lbs.) and/or have a body mass index (BMI) calculated from your height and weight that is less than 18.5 kg/m2 or more than 35.0; • have a positive HIV or hepatitis test result, abnormal laboratory test results that are not due to a transient (passing) condition, or an abnormal electrocardiogram (ECG); • Are pregnant or planning to become pregnant during the study or a minimum of 30 days after the study, or if you are breastfeeding, or if you have any medical conditions that could ...
Type Description. 5.1.5.3. In case of a tyre test vehicle
Type Description. OHIP Number Each eligible resident of the Province of Ontario that registers for the Ontario Health Insurance Plan (OHIP) is assigned a unique 10-digit health number, which may be followed by a single letter or two letter version code. Employee Number In Canada, an Employee Number is a unique number ascribed to each employee by employers for record-keeping and bookkeeping purposes. SIN A Social Insurance Number (SIN) is a 9-digit number required to work in Canada and/or access government programs and benefits. Financial Information In the context of this review, Financial Information will include any of the following: (i) a credit card number or (ii) bank account number. Address It is possible that some documents may not include an Affected Class Member’s name, but may have their mailing address or an email address on the document.
Type Description. 1 Delivery schedule line number Att Identifier Identifier The unique number given by the issuer to identify a delivery schedule line within a Delivery schedule message.
Type Description. 0..1 Address identification Att Identifier Identifier The unique identification of a location based on the Duns (Duns & Bradstreet) number of the company followed by four numeric digits. 1 Address line one Att Text Line one The first line of the address.
AutoNDA by SimpleDocs

Related to Type Description

  • Work Description T-804 Opening Roads - Removal of closure devices, cleaning ditches, removing berms, and blading the traveled-way T-811 Closing Roads - Entrance treatment for 150' cross-rip; debris block (slash, earth, berm, rocks, etc.) + seed + water bar T-811 Closing Roads - Water bar frequency per BMPs for remainder of road T-811 Closing Roads - Engineering Rep. or Construction Inspector must be notified prior to performing closeout NFSR Road No. Lane Width & Maintenance Level Mile Marker Begin End 9302 Single Lane / Level 2 NFSR 300 0.00 END 0.58

  • Service Description The Parties will provide Common Channel Signaling (CCS) to one another via Signaling System 7 (SS7) network Interconnection, in accordance with prevailing industry standards. Use of a third party provider of SS7 trunks is permitted.

  • Project Description In two or three brief sentences, provide a concise description of your exhibition. Include the subject matter, type of objects to be included (paintings, sculpture, manuscripts, etc.), those responsible for organizing the exhibition, and catalogue author(s).

  • Product Description The lead products covered by this Settlement Agreement are limited to following Amazon Identification Number (ASIN) B0932PW2FY with the description, "YALANLE 63/37 Solder Tin Lead Rosin Core Solder Wire For Electrical Soldering and DIY 0.22lbs (0.8mm/100g)," which was offered for sale by the Settling Entity on xxxxxx.xxx, hereinafter the “Product” or “Products.”

Time is Money Join Law Insider Premium to draft better contracts faster.